An anti-HIV peptide construct derived from the cleavage region of the Env precursor acts on Env fusogenicity through the presence of a functional cleavage sequence

Virology

Volumn 247, Issue 2, 1998, Pages 137-143

  Barbouche, Rym ^a   Sabatier, Jean Marc ^a   Fenouillet, Emmanuel ^a  

^a CNRS   (France)

Author keywords

Anti HIV peptides; Env activity; gp160 cleavage; HIV Env; Protein processing

Indexed keywords

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; SEQUENCE ANALYSIS; VACCINIA VIRUS; VIRUS ENVELOPE; VIRUS INHIBITION;

ANIMALIA; CARNATION LATENT VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES; VACCINIA; VACCINIA VIRUS;

EID: 0032146244     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9239     Document Type: Article

References (35)

1. Barbouche R., Fenouillet E., Papandréou M.-J., Kiény M. P., Sabatier J. M. Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials. J. Pept. Res. 52:1998a.
2. 3. J. Pept. Sci. 1998b.
3. Benjouad A., Chapuis F., Fenouillet E., Gluckman J. C. Multibranched peptide constructs derived from the V3 loop of envelope glycoprotein gp120 inhibit human immunodeficiency virus type 1 infection through interaction with CD4. Virology. 206:1995;457-465.
4. Bosch V., Pawlita M. Mutational analysis of the human immunodeficiency virus type 1 env gene product proteolytic cleavage site. J. Virol. 64:1990;2337-2344.
5. Brakch N., Dettin M., Scarinci C., Seidah N., Di Bello C. Structural investigation and kinetic characterization of potential cleavage sites of HIV gp160 by human furin and PC1. Biochem. Biophys. Res. Commun. 213:1995;356-361.
6. Callebaut C., Jacotot E., Guichard G., Krust B., Rey-Cuille M. A., Cointe D., Benkirane N., Blanco J., Muller S., Briand J. P., Hovanessian A. Inhibition of HIV infection by pseudopeptides blocking viral envelope glycoprotein-mediated membrane fusion and cell death. Virology. 218:1996;181-192.
7. De Rossi A., Pasti M., Mammano F., Panozzo M., Dettin M., Di Bello C., Chieco-Bianchi L. Synthetic peptides from the principal neutralizing domain of human immunodeficiency virus type 1 (HIV-1) enhance HIV-1 infection through a CD4-dependent mechanism. Virology. 184:1991;187-196.
8. Decroly E., Benjannet S., Savaria D., Seidah N. Comparative functional role of PC7 and furin in the processing of the HIV envelope glycoprotein gp160. FEBS Lett. 405:1997;68-72.
9. Decroly E., Wouters S., Di Bello C., Lazure C., Ruysschaert J. M., Seidah N. Identification of the paired basic convertases implicated in HIV gp160 processing based on in vitro asays and expression in CD4+ cells. J. Biol. Chem. 271:1996;30442-30450.
10. Decroly E., Vandenbranden M., Ruysschaert J. M., Cogniaux J., Jacob G. S., Howard S. C., Marshall G., Kompelli A., Basak A., Jean F., Lazure C., Benjannet S., Chrétien M., Day R., Seidah N. The convertases furin and PC1 can both cleave the human immunodeficiency virus (HIV)-1 envelope glycoprotein gp160 into gp120 (HIV-I SU) and gp41 (HIV-I TM). J. Biol. Chem. 269:1994;12240-12247.
11. Dubay J., Dubay S., Hunter E. Analysis of the cleavage site of the HIV glycoprotein: Requirement of precursor cleavage for glycoprotein incorporation. J. Virol. 69:1995;4675-4682.
12. Earl P., Moss B., Doms R. W. Folding, interaction with Bip, assembly and transport of the human immunodeficiency virus type 1 envelope protein. J. Virol. 65:1991;2047-2055.
13. Einfeld D. Maturation and assembly of retroviral glycoproteins. Curr. Top. Microbiol. 214:1996;133-176.
14. Fenouillet E., Gluckman J. C. Immunological analysis of human immunodeficiency virus type 1 envelope glycoprotein proteolytic cleavage. Virology. 187:1992;825-828.
15. Fenouillet E., Gluckman J. C. Effect of glucosidase inhibitor on the bioactivity and immunoreactivity of human immunodeficiency virus type 1 envelope glycoprotein. J. Gen. Virol. 72:1991;1919-1926.
16. Fenouillet E., Jones I. M. The glycosylation of human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) is important for the efficient intracellular transport of the envelope precursor gp160. J. Gen. Virol. 76:1995;1509-1515.
17. Fenouillet E., Miquelis R., Drillien R. Biological properties of recombinant HIV envelope synthesized in glycosylation mutant CHO cell lines. Virology. 218:1996;224-231.
18. Fenouillet E., Jones I. M., Powell B., Schmitt D., Kiény M. P., Gluckman J. C. Functional role of the glycan cluster of HIV-1 transmembrane glycoprotein gp41. J. Virol. 67:1993;150-160.
19. Fenouillet E., Papandréou M. J., Jones I. M. Recombinant HIV envelope expressed in an a-glucosidase I-deficient CHO cell line and its parental cell line in the presence of 1-deoxynojirimycin is functional. Virology. 231:1997;89-95.
20. Freed E., Myers D., Risser R. Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor. J. Virol. 63:1989;4670-4675.
21. Gu M., Rapaport J., Leppla S. Furin is important but not essential for the proteolytic maturation of gp160 of HIV-1. FEBS Lett. 365:1995;95-97.
22. Hallenberger S., Moulard M., Sordel M., Klenk H. D., Garten W. The role of eukaryotic subtilisin like endoproteases for the activation of HIV glycoproteins in natural host cells. J. Virol. 71:1997;1036-1045.
23. Hallengerger S., Bosch V., Angliker H., Shaw E., Klenk H. D., Garten W. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature. 360:1992;358-361.
24. Inocencio N., Susic J., Moehring J., Spence M., Moehring T. Endoprotease activities other than furin and PACE4 with a role in processing of HIV-1 gp160 glycoproteins in CHO-K1 cells. J. Biol. Chem. 272:1997;1344-1348.
25. Kieny M. P., Lathe R., Rivière Y., Dott K., Schmitt D., Girard M., Montagnier L., Lecocq J. P. Improved antigenicity of the HIV env protein by cleavage site removal. Protein Eng. 2:1988;219-225.
26. McCune J. M., Rabin L. B., Feinberg M. B., Lieberman M., Kosek J. C., Reyes G. R., Weissman I. L. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell. 53:1988;55-67.
27. Moore J. P., Jameson B. A., Weiss R. A., Sattentau Q. The HIV-cell fusion reaction. Viral Fusion Mechanisms. 1993;CRC Press. p. 230-289.
28. Morikawa Y., Barsov E., Jones I. Legitimate and illegitimate cleavage of human immunodeficiency virus glycoproteins by furin. J. Virol. 67:1993;3601-3604.
29. Neurath A., Strick N., Jiang S. Synthetic peptides and anti-peptide antibodies as probes to study interactions involved in virus assembly: The envelope of HIV-1. Virology. 188:1992;1-13.
30. Neurath A., Lin K., Strick N., Jiang S. Two partially overlapping antiviral peptides from the external portion of HIV type 1 glycoprotein 41, adjoining the transmembrane region, affect the glycoprotein 41 fusion domain. AIDS Res. Hum. Retroviruses. 11:1995;189-190.
31. Ohnishi Y., Shioda T., Nakayama K., Iwata S., Gotoh B., Hamaguchi M., Nagai Y. A furin defective cell line is able to process correctly the gp160 of HIV-1. J. Virol. 68:1994;4075-4079.
32. Pfeiffer T., Zentgraf H., Freyaldenhoven B., Bosch V. Transfer of endoplasmic reticulum and Golgi retention signals to human immunodeficiency virus type 1 gp 160 inhibits intracellular transport and proteolytic processing of viral glycoprotein but does not influence the cellular site of virus particle budding. J. Gen. Virol. 78:1997;1745-1753.
33. Sabatier J. M., Mabrouk K., Moulard M., Rochat H., Van Rietschoten J., Fenouillet E. Anti-HIV activity of multibranched peptide constructs derived either from the cleavage sequence or from the transmembrane domain (gp41) of the human immunodeficiency virus type 1 envelope. Virology. 223:1996;406-408.
34. Slepushkin V., Kornilaeva G., Andreev S., Sidorova M., Petrukina A., Matsedvitch G., Raduk S., Grigoriev V., Marakova T., Lukashov V., Karamov E. Inhibition of human immunodeficiency virus type 1 (HIV-1) penetration into target cells by synthetic peptides mimicking the N-terminus of the HIV-1 transmembrane glycoprotein. Virology. 194:1993;294-301.
35. Yahi N., Fantini J., Mabrouk K., Tamalet C., De Micco P., Rochat H., Van Rietschoten J., Sabatier J. M. Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages. J. Virol. 68:1994;5714-5720.